Chugai to Commercialize Alnylam’s RNAi Hypertension Drug in Japan

Chugai Pharmaceutical said on April 19 that it has earned the commercial rights in Japan for zilebesiran, an investigational RNAi therapeutic for hypertension originated by Alnylam Pharmaceuticals and is being jointly developed with Roche. Chugai signed a commercial license agreement...read more